Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Publication year range
1.
Am J Cardiol ; 94(11): 1367-72, 2004 Dec 01.
Article in English | MEDLINE | ID: mdl-15566905

ABSTRACT

Although dobutamine-atropine stress echocardiography (DASE) is an established method for evaluating patients who have coronary artery disease (CAD), it can increase test duration and a patient's exposure to large doses of dobutamine. New protocols, including the early injection of atropine during dobutamine stress echocardiography (EA-DSE), have been proposed to decrease test duration. This study compared the safety, efficacy, and accuracy of EA-DSE with those of DASE. We retrospectively evaluated 3,163 patients who underwent DASE and 1,664 patients who underwent EA-DSE over a period of 12 years. In EA-DSE, atropine at a dose 50% stenosis) was assessed in patients who underwent quantitative angiography

Subject(s)
Anti-Arrhythmia Agents/administration & dosage , Anti-Arrhythmia Agents/adverse effects , Atropine/administration & dosage , Atropine/adverse effects , Coronary Artery Disease/diagnostic imaging , Echocardiography, Stress/methods , Aged , Anti-Arrhythmia Agents/therapeutic use , Atropine/therapeutic use , Drug Administration Schedule , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Predictive Value of Tests , Retrospective Studies , Sensitivity and Specificity
2.
Rev. bras. ecocardiogr ; 17(3): 21-30, jul.-set. 2004. ilus, tab, graf
Article in Portuguese | LILACS | ID: lil-397766

ABSTRACT

RESUMO: Objetivo: Determinar a segurança, eficácia, e acurácia diagnóstica da infusão precoce de atropina durante a ecocardiografia sob estresse peladobutamina (AP-EED), em comparação com o protocolo convencional de dobutamina-atropina (EEDA), em pacientes com doença arterial coronariana (DAC) conhecida ou suspeita. Introdução: Embora a EEDA seja um método bem estabelecido para avaliar pacientes com DAC, pode resultar em longa duração do teste e exposição dos pacientes a altas doses de dobutamina. Novos protocolos, incluindo AP-EED, têm sido propostos para reduzir aduração do teste. Métodos: Estudamos retrospectivamente 3163 pacientes submetidos a EEDA e 1664 pacientes submetidos a AP-EED, em um período de 12 anos. No protocolo EEDA, atropina foi injetada apenas na dose máxima de dobutamina, enquanto na AP-EED atropina foi iniciada com 20mcg/Kg/min de dobutamina se a freqüência cardíaca estivesse <100 bpm, até 2mg. A acurácia diagnóstica para detecção de DAC (estenose >50 por cento em >_1 artéria coronariana) foi avaliada em pacientes que realizaram angiografia quantitativa dentro de três meses após o ecocardiograma sob estresse. Resultados: A dose total de dobutamina utilizada na AP-EED foi menor que na EEDA (31+- 6 verso 36 +- 6 mcg/Kg/min;p<0,OOO1), enquanto a dose de atropina foi maior (0,8+-0,5 verso 0,5+-0,25 mg; p<0,0001). Com AP-EED houve redução significativa da duração do teste (12,4+-2,0 verso 14,6+-2,5 minutos;p<0,OO01), maior porcentagem de testes eficazes (88 por cento verso 81 por cento;p

Subject(s)
Humans , Male , Atropine/adverse effects , Atropine/therapeutic use , Echocardiography, Stress/adverse effects , Echocardiography, Stress/methods , Coronary Angiography/methods , Myocardial Ischemia/diagnosis , Myocardial Ischemia/therapy
3.
Ann Thorac Surg ; 76(2): 607-10, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12902116

ABSTRACT

Humoral response emerges as an important component in acute graft rejection and a new challenge to clinicians in posttransplant care. Management of recurrent episodes and persistent activation of the humoral component of the immune system, despite the usual therapeutic approach to rejection, remains unknown. This article describes the successful use of methotrexate as an option for rescuing a graft in this worrisome situation.


Subject(s)
Cardiomyopathy, Dilated/surgery , Graft Rejection/prevention & control , Heart Transplantation/immunology , Methotrexate/administration & dosage , Acute Disease , Adult , Antibody Formation/physiology , Cardiomyopathy, Dilated/diagnosis , Dose-Response Relationship, Drug , Drug Administration Schedule , Graft Survival , Heart Transplantation/adverse effects , Heart Transplantation/methods , Humans , Male , Prognosis , Transplantation Immunology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL